Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Furmonertinib 160 mg, Q.D.
DRUG
2 trials
Sponsors
Peking Union Medical College
, Chongqing University Cancer Hospital
Conditions
Brain Metastases
EGFR G719X
EGFR L861Q
EGFR S768I
EGFR-mutation
Furmonertinib
NSCLC
Non-small Cell Lung Cancer
Phase 2
Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)
Completed
NCT05465343
Peking Union Medical College
Brain Metastases, EGFR-mutation, Furmonertinib +1
Start: 2022-07-11
End: 2025-12-12
Updated: 2025-12-19
First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation
NCT05548348
Chongqing University Cancer Hospital
EGFR G719X, EGFR L861Q, EGFR S768I +1
Start: 2022-09-26
End: 2025-10-31
Target: 30
Updated: 2022-09-21
Related Papers
High-dose furmonertinib in <i>EGFR</i> -mutated advanced NSCLC with brain metastases after EGFR-TKI resistance: The iFORCE phase II trial.
Journal of Clinical Oncology
2026-05-28
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies.
2023-04-28
15 citations